Assessment of quality of life in patients with chronic myeloid leukemia undergoing

Authors

  • Enzo Garcia Prado Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde https://orcid.org/0009-0008-8993-5625
  • Lucas Bernucci Gozzo Barbosa Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde https://orcid.org/0009-0007-6142-4404
  • Manoela Mesquita Rayol Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde https://orcid.org/0009-0008-0822-1939
  • Mariana Vieira Pacheco Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde https://orcid.org/0009-0006-3865-5346
  • Marcelo Gil Cliquet Pontifícia Universidade Católica de São Paulo. Faculdade de Ciências Médicas e da Saúde

DOI:

https://doi.org/10.23925/1984-4840.2026v28a3

Keywords:

Chronic Myeloid Leukemia, Quality of Life, Surveys and Questionnaires

Abstract

Objectives: To evaluate the quality of life and the clinical, demographic, and laboratory data of patients with chronic myeloid leukemia (CML) undergoing treatment at the Conjunto Hospitalar de Sorocaba (CHS). Methods: A total of 100 medical records of patients with CML under treatment at CHS were analyzed. Information on sex, current age, age at diagnosis, initial and current treatment, and diagnostic data (hemoglobin, platelet, and leukocyte levels, and spleen size) was collected. Additionally, 91 SF-36 questionnaires (Brazilian version) were administered, either in person or virtually. Results: Female patients were predominant (54%). The current mean age was 55 years, and the mean age at diagnosis was 47.5 years. At the time of suspected CML, 84% of patients received hydroxyurea; after confirmation, 100% initiated imatinib. Currently, 57% are on imatinib, 27% on nilotinib, 15% on dasatinib, and 1% on ponatinib. The main laboratory findings at diagnosis were anemia (76.9%) and leukocytosis (86.9%). Among the 72 medical records with spleen-related data, 68% showed splenomegaly. Of the 91 SF-36 participants, 56% were women. Scores in all eight domains were lower than those of the normative Brazilian population. Female patients scored lower than males across all domains. The lowest scores were in the vitality and general health domains, consistent with patterns observed in the Brazilian population. Conclusion: CML adversely affects patients’ quality of life. The patients evaluated had lower quality-of-life scores than the general population, particularly among women and in the domains of vitality and general health.

References

1. Valencia A, Cervera J, Such E, Barragán E, Bolufer P, Fuster O, et al. Complex variant t(9;22) chromosome translocations in five cases of chronic myeloid leukemia. Adv Hematol. 2009;2009:187125. doi: 10.1155/2009/187125.

2. Sossela FR, Zoppas BCA, Weber LP. Chronic myeloid leukemia: clinical aspects, diagnosis and main changes observed in complete blood count. Rev Bras Anál Clin. 2017;49(2):127-30. doi: 10.21877/2448-3877.201700543.

3. Castro MA, Castro MA, Peleja SB, Barbosa AP, Tavares RS, Roberti MRF. Ocorrência de múltiplas neoplasias em paciente portador de leucemia mieloide crônica: relato de caso. Rev Bras Cancerol. 2012;58(2):251-5. doi: 10.32635/2176-9745.RBC.2012v58n2.627.

4. Almeida A, Castro I, Coutinho J, Guerra L, Marques H, Pereira AM. Recomendações para o diagnóstico, tratamento e monitorização da leucemia mielóide crónica. Acta Med Port. 2009;22(5):537–44.

5. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol. 1999;39(3):143-50.

6. Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii72–7. doi: 10.1093/annonc/mds228.

7. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981-7. doi:10.1182/blood-2011-08-358135.

8. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. doi: 10.1056/NEJMoa022457.

9. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917-27. doi: 10.1056/NEJMoa1609324.

10. Di Felice E, Roncaglia F, Venturelli F, Mangone L, Luminari S, Cirilli C, et al. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study. BMC Cancer. 2018;18:1069. doi: 10.1186/s12885-018-4984-3.

11. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440–54. doi: 10.1016/j.mayocp.2015.08.010.

12. Funke VM, Setubal DC, Ruiz J, Azambuja AP, Lima DH, Kojo TK, et al. O tratamento da leucemia mielóide crônica com mesilato de imatinibe. Rev Bras Hematol Hemoter. 2008;30(Supl 1):27–31. doi: 10.1590/S1516-84842008000700008.

13. Laguardia J, Campos MR, Travassos C, Najar AL, Anjos LA, Vasconcellos MM. Brazilian normative data for the Short Form 36 questionnaire, version 2. Rev Bras Epidemiol. 2013;16(4):889–97. doi: 10.1590/S1415-790X2013000400009.

14. Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep. 2021;16(6):491-9. doi:10.1007/s11899-021-00656.

15. Bortolheiro TC, Chiattone CS. Leucemia mielóide crônica: história natural e classificação. Rev Bras Hematol Hemoter. 2008;30(Suppl 1):3–7. doi: 10.1590/S1516-84842008000700003.

16. Ribeiro ACA, Pratti JES, Nogueira TA, Cordeiro BC. Acompanhamento farmacoterapêutico e a detecção de reações adversas a inibidores de tirosinoquinase utilizados no tratamento da leucemia mieloide crônica. Braz J Health Rev. 2020;3(6):19438–54. doi: 10.34119/bjhrv3n6-323.

17. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. doi: 10.1038/s41375-020-0776-2.

18. Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42–50. doi: 10.1001/jamaoncol.2020.5774.

Downloads

Published

2026-01-29

How to Cite

Prado, E. G., Barbosa, L. B. G., Rayol, M. M., Pacheco, M. V., & Cliquet, M. G. (2026). Assessment of quality of life in patients with chronic myeloid leukemia undergoing. Revista Da Faculdade De Ciências Médicas De Sorocaba, 28(Fluxo contínuo), e71517. https://doi.org/10.23925/1984-4840.2026v28a3

Issue

Vol. 28 No. Fluxo contínuo (2026)

Section

Original Article

Categories

License

Copyright (c) 2026 Revista da Faculdade de Ciências Médicas de Sorocaba

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Os autores no momento da submissão transferem os direitos autorais, assim, os manuscritos publicados passam a ser propriedade da revista.

O conteúdo do periódico está licenciado sob uma Licença Creative Commons 4.0, esta licença permite o livre acesso imediato ao trabalho e que qualquer usuário leia, baixe, copie, distribua, imprima, pesquise ou vincule aos textos completos dos artigos, rastreando-os para indexação, passá-los como dados para o software, ou usá-los para qualquer outra finalidade legal.